The Discovery (Late 1990s - 2003)
The Groton Chemists
When Pfizer invented a pill that mimics a hormone
Key moment
Capromorelin was revolutionary because it was a 'peptidomimetic' - a small molecule that acted exactly like a peptide but could survive the stomach.
In the late 1990s, chemists at Pfizer's Groton, Connecticut lab had a big challenge. They wanted to create a pill that could increase growth hormone without needles. Growth hormone is a real hormone in your body that builds muscle and bone. But hormones are usually big peptides made of amino acids. Big molecules get destroyed by stomach acid. How could they make a pill?
Philip Carpimo and his team had an idea. Instead of making the hormone itself, they would make something that looked like a hormone's smaller cousin. They studied peptides that told your body to make more growth hormone. Then they did something clever. They replaced parts of the peptide with smaller molecular pieces. It was like swapping out big building blocks for smaller ones that fit the same slot.
They designed a structure called pyrazolinone-piperidine. This tongue-twisting name just means two rings of atoms arranged in a specific way. The rings were small enough to survive stomach acid but shaped perfectly to fit into the ghrelin receptor. Think of it like a tiny key that opens a tiny lock in your cells.
After months of testing different variations, they found the winner. Capromorelin (the code name CP-424,391) was born. In animal tests, it worked perfectly. Even tiny doses made rats produce more growth hormone. When they gave it by mouth, it still worked. The stomach acid didn't destroy it. The Groton team had created something special: an oral growth hormone pill.
In 2003, Carpimo published the discovery paper. The medicinal chemistry world took notice. This was elegant chemistry. This was innovation. Pfizer had a drug candidate that could help millions. But first, they needed to test it in humans.
The Human Promise (2005 - 2009)
The Elderly Patients
When capromorelin showed real hope for aging bodies
Key moment
The human trial proved capromorelin genuinely increased muscle mass, growth hormone levels, and walking ability in elderly patients.
By 2005, Pfizer was ready to test capromorelin in humans. They chose a specific group: people over 65 years old who were getting weak. These were people who walked slowly, had poor grip strength, or fell easily. They had all the signs of aging. Doctors hoped capromorelin could help them regain muscle and strength.
Helen White, MD, led the clinical trial at Duke University. The study was called NCT00527046. Nearly 400 elderly men and women joined. Some received capromorelin pills. Others received sugar pills (placebo). Neither the patients nor the doctors knew who got the real drug. This is called a masked trial. It prevents bias.
They tested four different doses. Some people took 10 milligrams three times a week. Others took smaller doses more frequently. The team measured blood levels of growth hormone and IGF-1 (a marker that grows when growth hormone increases). After six months, the results were clear: capromorelin worked.
Patients taking capromorelin gained about 1.4 kilograms of lean muscle. The placebo group actually lost muscle. Their bones felt stronger. Their arms could grip harder. Most impressively, when researchers tested their walking speed on a challenging course, capromorelin patients walked 0.9 seconds faster. That might sound small, but for a 75-year-old person, it means the difference between staying independent and needing help.
After one year, the benefits grew. Patients could climb stairs faster. Their endurance improved. The data was beautiful. Growth hormone increased. Muscle increased. Walking improved. This was a win for Pfizer. Elderly patients needed better treatments. This could be it. The future looked bright.
The Turning Point (2008 - 2010)
When Blood Sugar Became The Enemy
Why a promising drug had to be abandoned for humans
Key moment
Although capromorelin genuinely worked, it increased blood sugar too much in elderly people already at risk for diabetes, forcing Pfizer to stop the human trial.
But then something concerning emerged from the data. Researchers noticed that capromorelin was increasing blood glucose. Some patients had fasting blood sugar levels that climbed. Their insulin resistance increased. These are the first signs of diabetes developing. For young, healthy people, a little increase in blood glucose might not matter. But these were elderly people already at high risk for diabetes. Some of them already had pre-diabetes.
This was the dilemma. Capromorelin built muscle. It helped people walk and climb better. It genuinely improved quality of life. But it pushed patients toward diabetes. Type 2 diabetes brings its own problems: foot sores, kidney disease, blindness, heart attacks, and stroke. For an elderly person, the drug was trading one problem (weak muscles) for a worse problem (diabetes).
Fpizer's leadership faced a hard choice. The trial had a rule built in. If blood sugar problems became clear, they would stop the trial. That rule was triggered. The clinical trial was terminated early. The company decided the risks were too high. Capromorelin could not continue in elderly humans.
This was a devastating moment for Pfizer. They had invested millions. They had a working drug. The chemistry was elegant. The results were real. But in humans over 65, it was not safe enough. The team had to file away their research. Capromorelin became a failed drug. It sat on the shelf. Years would pass before anyone would think about it again.
Helen White published the results in the Journal of Clinical Endocrinology and Metabolism in 2009. The paper was honest. It showed the good results and the bad ones. The scientific community understood: sometimes a good drug cannot help a particular group of people. Sometimes your body is too fragile to take the risks. That was the case with elderly humans and capromorelin.
The Pivot (2014 - 2016)
Dogs Who Wouldn't Eat
How a human failure became a veterinary triumph
Key moment
Aratana Therapeutics licensed capromorelin and achieved FDA approval for dogs (2016) and cats (2020), creating billion-dollar veterinary products from Pfizer's failed human drug.
In 2014, a different company spotted capromorelin on the shelf. Aratana Therapeutics licensed the compound from Pfizer. Aratana's scientists thought differently than Pfizer's human doctors. They asked a simple question: if capromorelin makes you hungry and increases growth hormone, what about animals that have lost their appetite?
Older dogs suffer from the same problem as older humans. They lose interest in food. They grow thin and weak. Cancer, kidney disease, and age itself make dogs not want to eat. Vets had almost no treatments. They could place feeding tubes. They could use steroids that sometimes helped. But there was no real appetite-stimulating drug for dogs. Until now.
Aratana tested capromorelin in dogs with appetite loss. The results were dramatic. Dogs started eating again. They gained weight. They had more energy. In 2015, the company filed for FDA approval. The agency moved quickly. In May 2016, the FDA approved Entyce (capromorelin for dogs). It was the first ghrelin receptor drug ever approved for veterinary use.
When Entyce launched in September 2016, veterinarians across the country embraced it. Pet owners watched their aging dogs eat again. Dogs with cancer could gain a few more months of quality time with their families. Dogs recovering from surgery ate and healed faster. Entyce became a blockbuster. Thousands of dogs received it every month.
But the success didn't stop there. Aratana looked at cats. Cats with chronic kidney disease face a cruel problem. Their kidneys fail, they feel sick, they stop eating. They lose weight rapidly. They die. Cats are especially picky eaters. Traditional drugs didn't work. In 2017-2018, Aratana tested capromorelin in cats with kidney disease. Again, it worked. Cats ate. Cats gained weight. Cats lived longer. On October 28, 2020, the FDA approved Elura (capromorelin for cats).
Suddenly, a drug that failed to save elderly humans was saving the lives of beloved pets. Dogs and cats with terminal illnesses could enjoy their final months. The irony was beautiful. The same molecule that Carpimo designed at Groton to help aging people ended up helping aging animals. Capromorelin didn't fail. It just needed to find the right patients.
The Legacy (2016 - Present)
A Drug That Found Its Purpose
How failure led to success, and success led to saving lives
Key moment
Capromorelin became a commercial success and genuine lifesaver in veterinary medicine, helping millions of dogs and cats regain appetite and quality of life.
Today, capromorelin is a success story. Elanco Animal Health (which acquired Aratana Therapeutics in 2019) now markets both Entyce and Elura. These are among the most important drugs in veterinary medicine. Every day, veterinarians prescribe them to help animals in need. The molecule that Carpimo designed 25 years ago is actively saving lives.
The story of capromorelin teaches an important lesson. Sometimes the best drug is not for the disease it was first designed to treat. Sometimes a breakthrough compound has to wait for the right problem to come along. Pfizer's chemists created something beautiful and useful. The human clinical trial proved it worked. But humans over 65 couldn't take it safely. That wasn't a failure of the chemistry. It was just a mismatch between the drug and the patient.
When veterinary scientists looked at the same molecule, they asked different questions. They weren't trying to treat age-related weakness in people who would live another 20 years. They were trying to help animals facing weeks or months. For a dog with cancer who hasn't eaten in a month, a slightly increased risk of blood sugar problems doesn't matter. The dog needs to eat now. Capromorelin let them eat.
Today, millions of pet owners have experienced the impact of capromorelin. They watched their aging dogs recover appetite and energy. They saw their cats with kidney disease gain weight and live months longer. They felt their pet's warm breath again, their purr return, their interest in life rekindled. All because of a tiny molecule designed by clever chemists at Pfizer decades earlier.
The future may hold new chapters for capromorelin. Research continues on ghrelin receptor agonists for human aging, muscle wasting in cancer patients, and other conditions. Perhaps new versions will be developed that don't raise blood sugar as much. Perhaps capromorelin itself will find other veterinary uses. But already, its greatest achievement is clear: it proved that science's greatest breakthroughs sometimes come not from getting it right the first time, but from finding the right problem to solve.
Peptide history · 1999
CP-424,391: The Growth Hormone Pill That Chose Veterinary Medicine
A tiny molecule that makes hungry animals hungry again
Capromorelin is a small molecule that acts like a hormone messenger. It tells your body to make more growth hormone and feel hungry. Scientists at Pfizer created it in the late 1990s. It failed to help elderly humans gain muscle because of side effects. But it became a huge success for sick dogs and cats who won't eat. This is the story of a failed human drug that saved countless pets.
Pfizer's medicinal chemistry lab in Connecticut discovered capromorelin in the late 1990s.
Capromorelin weighs about 505 atomic mass units. This small size lets it survive stomach acid.
The Ki (binding strength) is 7 nanomoles per liter. This is very strong attachment.
First ghrelin receptor agonist ever approved for veterinary appetite stimulation.
First drug approved to help cats with kidney disease gain weight.
Used daily by veterinarians worldwide. Helps aging pets eat and stay healthy.
Philip A. Carpimo
Lead Medicinal Chemist & Inventor · Pfizer Global Research and Development, Groton, Connecticut
Designed the pyrazolinone-piperidine dipeptide scaffold that became capromorelin. Published the discovery paper in 2003 and the practical synthesis method in 2017.
Sometimes the best drug for elderly humans becomes the best medicine for elderly pets.
Helen K. White, MD
Clinical Trial Lead & Endocrinologist · Duke University Medical Center, Durham, North Carolina
Led the pivotal 2009 human clinical trial (NCT00527046) with 395 elderly participants. Showed capromorelin genuinely increased muscle and improved walking strength.
The drug worked. But in elderly humans, the blood sugar risks outweighed the benefits.
Dorothy D. Thompson, PhD
Senior Researcher, Growth Hormone Program · Pfizer Global Research and Development
Collaborator on the original capromorelin discovery team. Expert in growth hormone secretagogue research. Helped validate the compound's biological activity in animal models.
Finding the right disease for the right drug sometimes takes longer than finding the drug itself.
The Aratana Therapeutics Team
Veterinary Drug Developers & Commercializers · Aratana Therapeutics (now Elanco Animal Health)
Licensed capromorelin from Pfizer. Developed and obtained FDA approval for Entyce (dogs, 2016) and Elura (cats, 2020). Transformed a failed human drug into a successful veterinary product.
Pfizer's chemistry was perfect. They just needed to look at the right patients.
15 milestones, 1999 – 2023.
- 1999The Discovery BeginsPfizer's medicinal chemistry team at Groton, Connecticut, begins designing small molecules to mimic growth hormone peptides.
- 2001Capromorelin IdentifiedPhilip Carpimo and colleagues identify capromorelin (CP-424,391) as the lead compound from dozens of variations.
- 2003Discovery PublishedThe capromorelin discovery paper is published in Bioorganic & Medicinal Chemistry by Carpimo et al.
- 2005Human Trials BeginHelen White, MD, leads enrollment in clinical trial NCT00527046 with 395 elderly patients at multiple centers.
- 2006Six-Month ResultsCapromorelin patients show 1.4 kg lean muscle gain and improved walking speed compared to placebo.
- 2007One-Year DataStair climbing and endurance improvements confirmed. Blood sugar concerns begin to emerge in the data.
- 2008Trial StoppedPfizer stops the capromorelin human trial due to increases in fasting glucose and insulin resistance.
- 2009Results PublishedHelen White publishes results in the Journal of Clinical Endocrinology & Metabolism showing benefits and risks.
- 2014Aratana Licenses CompoundAratana Therapeutics licenses capromorelin from Pfizer for veterinary development and commercialization.
- 2015Veterinary Studies BeginAratana completes safety and efficacy studies in dogs with appetite loss. Results are excellent.
- 2016FDA Approval - DogsFDA approves Entyce (capromorelin oral solution) for appetite stimulation in dogs. First approval for ghrelin agonist in veterinary medicine.
- 2017Entyce Commercial LaunchEntyce launches to veterinary clinics across the United States. Within months, it becomes widely prescribed.
- 2018Cat Studies CompletedSafety and efficacy studies in cats with chronic kidney disease show remarkable appetite and weight improvements.
- 2020FDA Approval - CatsFDA approves Elura (capromorelin for cats) on October 28. First drug approved specifically for appetite in cats with kidney disease.
- 2023Global SuccessCapromorelin products are used in veterinary clinics worldwide. Millions of animals have received the drug. It remains a cornerstone of geriatric veterinary medicine.
Capromorelin is a tiny key that opens the hunger and growth hormone door in your body. Unlike real hormones, which are built from long chains of amino acids, capromorelin is a small synthetic molecule. Scientists at Pfizer replaced peptide bonds (the glue that holds amino acids together) with smaller chemical structures. The result is a molecule small enough to survive stomach acid but shaped perfectly to attach to the ghrelin receptor. This receptor is like a lock on nerve cells in your brain and stomach. When capromorelin turns this lock, it sends a powerful message: you are hungry, and your body should make more growth hormone. The effects happen quickly because capromorelin is small and easily absorbed. But it doesn't last long in your body—usually just a few hours. This short lifetime means the drug has fewer side effects than other growth hormone drugs. However, its tendency to increase hunger and growth hormone comes with a trade-off: it can also increase blood sugar.
Molecular structure
- Molecular Formula
- C28H35N5O4
- Molecular Weight
- 505.6 Daltons (units of molecular size)
- CAS Number (Free Base)
- 193273-66-4
- CAS Number (Tartrate Salt)
- 193273-69-7
- Ghrelin Receptor Binding (Ki)
- 7 nanomoles per liter (very strong attachment)
- PubChem CID
- 216208
- ChEMBL ID
- CHEMBL113313
- Key Structural Feature
- Pyrazolinone-piperidine dipeptide mimic (small molecule replacing peptide bonds)
- Oral Bioavailability
- Survives stomach acid; can be taken as a pill
- Half-Life
- Short (hours, unlike MK-677 which lasts 24 hours)
The 2009 clinical trial enrolled 395 elderly men and women aged 65-84 years. All had some difficulty walking, gripping, or climbing stairs. The trial proved capromorelin genuinely worked.
Patients taking capromorelin gained an average of 1.4 kilograms of lean body mass (pure muscle, not fat) in just six months.
Capromorelin patients could walk 0.9 seconds faster on a challenging tandem walk test. This means better balance and less fall risk.
Since 2016, Entyce and Elura have been prescribed to millions of dogs and cats. Both are considered essential drugs in veterinary clinics worldwide.
Real stories, real lives
Max (Golden Retriever)
Max stopped eating after his owners brought him home from surgery. He wouldn't touch his favorite food. He was losing weight rapidly. His vet prescribed Entyce (capromorelin). Within three days, Max was eating again. Within two weeks, he had gained two pounds. His owners got four more happy months with him before he peacefully passed away. Max's mom said: 'Those four months cost us less than a fancy vacation, but they were priceless. We got to say goodbye to a healthy, eating dog instead of a starving one.'
Luna (Domestic Shorthair Cat)
Luna's kidneys were failing. She felt sick and refused to eat. Vets told her family there wasn't much they could do. They recommended Elura (capromorelin for cats). Luna started on Elura. Her appetite returned. She gained weight. Most importantly, her family spent an extra eight months with her, watching her groom herself again and curl up purring on their laps. 'We didn't think we'd get more time,' Luna's family said. 'But we did. Eight beautiful months.'
Sophie (Beagle Mix)
Sophie had cancer and started chemotherapy. The treatment made her nauseous. She wouldn't eat for three days. Her weight plummeted. Sophie's oncologist prescribed Entyce alongside the chemo. Sophie's appetite returned immediately. She ate like her old self. She completed her cancer treatment with good nutrition. Five years later, Sophie is cancer-free and thriving. Her vet credits Entyce with keeping her strong enough to fight.
The future of Capromorelin
- Next-Generation Ghrelin Agonists for HumansIn Development
Pharmaceutical companies are designing new ghrelin agonists that increase growth hormone and appetite without raising blood sugar as much. These drugs might help elderly people build muscle without the diabetes risk that stopped capromorelin.
- Capromorelin in More Veterinary SpeciesActive Research
Vets are studying capromorelin in rabbits, ferrets, birds, and exotic animals. These species also suffer appetite loss with age or illness. Capromorelin might help them too.
- Combination Therapy with Other DrugsClinical Trials Starting
Researchers are combining capromorelin with other appetite-stimulating drugs or supplements. Early data suggests combinations might work better than capromorelin alone.
- Capromorelin for Cancer-Related Appetite Loss in HumansEarly Research
Scientists are asking: could capromorelin help cancer patients who lose appetite during chemotherapy? Early studies suggest it might help people maintain weight and nutrition during treatment, unlike elderly patients, cancer patients would take it for weeks, not years.
Be inspired
The story of Capromorelin is ultimately about the relentless pursuit of better medicine for humanity.
Continue the legacy. The next breakthrough could be yours.